Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders.

Abstract

This 12-week drug-monitoring study was conducted to evaluate the efficacy of Sanhelios Mussel Lyprinol Lipid Complex on 50 adult men and women with inflammatory rheumatoid arthritis. A total of 34 patients required drug therapy before and during the study. By the end of the study, 21 (62%) patients were able to reduce their dosage and 13 were able to terminate drug therapy. At the end of the treatment period, 38% were regarded symptom free, and the number of patients with severe pain decreased significantly from 60% at baseline to 25% at the completion of the trial. A significant effect was observed for each investigated parameter. The special combination of Lyprinol and omega-3 fatty acids was generally very well tolerated, with only one, nonserious adverse event (mild nausea) reported. This dietary supplement may therefore be considered an effective and well-tolerated component of treatment regimens for inflammatory rheumatoid arthritis.

• Authors: Joerg Gruenwald, Hans-Joachim Graubaum, Knuth Hansen, Barbara Grube
• Journal: Advances in therapy (Adv Ther) 2004 May-Jun Vol. 21 Issue 3 Pg. 197-201 ISSN: 0741-238X [Print] United States
• PMID: 15509136 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Lipids
• Pyrones
• lyprinol
• dehydroacetic acid
• Eicosapentaenoic Acid

Topics

• Adult
• Aged
• Arthritis, Rheumatoid (diagnosis, drug therapy)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Drug Therapy, Combination
• Eicosapentaenoic Acid (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Lipids (administration & dosage)
• Male
• Maximum Tolerated Dose
• Middle Aged
• Pain Measurement
• Prospective Studies
• Pyrones (administration & dosage)
• Range of Motion, Articular (drug effects, physiology)
• Risk Assessment
• Severity of Illness Index
• Treatment Outcome